Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Signs Two Deals for MicroRNA Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced two collaborations to advance its microRNA-based diagnostic tests.

The Rehovot, Israel-based company has signed agreements with Tel Hashomer Medical Research Infrastructure and Services and Carmel Medical Center, both also based in Israel, to develop and validate Rosetta's miRNA-based tests for indications related to its Gen 3 products.

The Gen 3 tests will focus on cardiovascular disease, neurodegenerative disease, women's health, and early detection of certain cancers. They are designed to leverage miRNA biomarkers found in body fluids, Rosetta said.

Financial and other terms of the deal were not disclosed.

"Our goal is to obtain proof-of-concept data on at least one of our Gen 3 products this year," Kenneth Berlin, president and CEO of Rosetta, said in a statement. "With encouraging preliminary data in two of these Gen 3 indications already, Rosetta will be conducting studies to determine if these results hold up over larger sample sizes."

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.